A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Phase 1

Terminated

• Conditions: Hepatic Impairment
• Interventions: Drug: Erdafitinib

• Registration Number: NCT03587363
• Lead Sponsor: Janssen Research & Development, LLC

Brief Summary

The primary purpose of the study is to characterize the single dose pharmacokinetic of erdafitinib in participants with impaired hepatic function relative to participants with normal hepatic function.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-07-04
• Study First Submitted QC: 2018-07-04
• Study First Posted: 2018-07-16
• Study Start: 2018-12-06
• Primary Completion: 2020-12-22
• Study Completion: 2020-12-22
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-31
• Last Update Posted: 2025-02-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Man or woman must have a clinically stable hepatic function as confirmed by the serum bilirubin and transaminase levels measured during screening and those measured on Day -1
• If a woman (a) must not be of childbearing potential postmenopausal or surgically sterile (b) must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 3 months after the study drug administration
• If a woman who is considered surgically sterile but not postmenopausal, must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening (exemptions: pregnancy test not required in female participants with prior hysterectomy or prior bilateral oophorectomy)
• If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 3 months after the study drug administration
• Participants with hepatic impairment must meet the Child-pug classification for mild, moderate or severe hepatic impairment and must have stable hepatic function

Exclusion Criteria

• History or current evidence of ophthalmic disorder, such as central serous retinopathy (CSR) or retinal vein occlusion, active wet age related macular degeneration, diabetic retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
• Any surgical or medical condition that may alter the absorption, metabolism, or excretion of the study drug (example, gastrectomy, Crohn's disease etc), with the exception of hepatic impairment
• History of drug abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 6 months before screening or positive test result(s) for drugs of abuse (including barbiturates, opiates, cocaine, cannabinoids, amphetamines, hallucinogens, and benzodiazepines) at screening and on Day -1
• Known allergy to the study drug or any of the excipients of the formulation (Physical Description of Study Drug[s], for a list of excipients)
• Donated blood or blood products or had substantial loss of blood (more than 500 milliliter [mL]) within 3 months before study drug administration or intention to donate blood or blood products during the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1: Normal Hepatic Function	Erdafitinib	Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
Cohort 2: Mild Hepatic Impairment	Erdafitinib	Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
Cohort 3: Moderate Hepatic Impairment	Erdafitinib	Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
Cohort 4: Severe Hepatic Impairment	Erdafitinib	Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.

Primary Outcome Measures

Name	Time	Method
Maximum Observed Plasma Concentration (Cmax)	Up to 21 days	Cmax is the maximum observed plasma concentration.
Terminal Elimination Half-life (t1/2term, Lambda)	Up to 21 days	t1/2term, Lambda is elimination half-life associated with the terminal slope (Lambda\[Z\]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/Lambda(Z).
Apparent Volume of Distribution (Vd/F)	Up to 21 days	Vd/F is apparent volume of distribution after extravascular administration, uncorrected for absolute BA.
Area Under Plasma Concentration-Time Curve (AUC)	Up to 21 days	AUC is area under plasma concentration-time curve.
Total Plasma Clearance (CL/F)	Up to 21 days	CL/F is total plasma clearance of drug after extravascular administration, uncorrected for absolute bioavailability (BA), calculated as Dose/AUC (0-infinity).
Time to Reach the Maximum Observed Plasma Concentration (Tmax)	Up to 21 days	Tmax is the time to reach maximum observed plasma concentration.

Secondary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Approximately 50 days	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily have a causal relationship with the relevant investigational product.

Trial Locations

Locations (2)

CRS Clinical Research Services Kiel GmbH; 🇩🇪 Kiel, Germany

APEX GmbH; 🇩🇪 Munchen, Germany